HER3 receptor is then the most frequent heterodimerization partner for HER2 receptor in HER2-positive breast cancer and this dimerization pair forms the most active kinase domain and the strongest PI3K/Akt signalling pathway stimulator (9). Here, ERBB2 is linked to breast carcinoma.